LoginSignup
Jazz Pharms logo

Jazz Pharms Stock

StockStock
ISIN: IE00B4Q5ZN47
Ticker: JAZZ
IE00B4Q5ZN47
JAZZ

Price

Frequently asked questions

What is Jazz Pharms's market capitalization?

The market capitalization of Jazz Pharms is $7.68B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Jazz Pharms's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Jazz Pharms is 17.90. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Jazz Pharms?

Jazz Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $7.10. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Jazz Pharms's stock?

Currently, 18 analysts cover Jazz Pharms's stock, with a consensus target price of $178.06. Analyst ratings provide insights into the stock's expected performance.

What is Jazz Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, Jazz Pharms reported a revenue of $3.99B.

What is the EBITDA for Jazz Pharms?

Jazz Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.35B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Jazz Pharms?

Jazz Pharms has a free cash flow of $1.10B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Jazz Pharms's stock?

The 5-year beta for Jazz Pharms is 0.58. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Jazz Pharms have, and what sector and industry does it belong to?

Jazz Pharms employs approximately 2,800 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Jazz Pharms's shares?

The free float of Jazz Pharms is 58.67M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $7.68B

5Y beta

 0.58

EPS (TTM)

 $7.10

Free Float

 58.67M

P/E ratio (TTM)

 17.90

Revenue (TTM)

 $3.99B

EBITDA (TTM)

 $1.35B

Free Cashflow (TTM)

 $1.10B

Pricing

1D span
$126.04$128.33
52W span
$99.06$134.17

Analyst Ratings

The price target is $178.06 and the stock is covered by 18 analysts.

Buy

14

Hold

4

Sell

0

Information

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

2,800

Biotechnology & Drugs

Health Care

Identifier

ISIN

IE00B4Q5ZN47

Primary Ticker

JAZZ

Knockouts

Join the conversation
Sign upLogin